TY - JOUR
T1 - Magnetic resonance imaging–guided stereotactic laser ablation therapy for the treatment of pediatric epilepsy
T2 - a retrospective multiinstitutional study
AU - Pediatric Stereotactic Laser Ablation Workgroup
AU - Arocho-Quinones, Elsa V.
AU - Lew, Sean M.
AU - Handler, Michael H.
AU - Tovar-Spinoza, Zulma
AU - Smyth, Matthew D.
AU - Bollo, Robert J.
AU - Donahue, David
AU - Perry, M. Scott
AU - Levy, Michael
AU - Gonda, David
AU - Mangano, Francesco T.
AU - Kennedy, Benjamin C.
AU - Storm, Phillip B.
AU - Price, Angela V.
AU - Couture, Daniel E.
AU - Oluigbo, Chima
AU - Duhaime, Ann Christine
AU - Barnett, Gene H.
AU - Muh, Carrie R.
AU - Sather, Michael D.
AU - Fallah, Aria
AU - Wang, Anthony C.
AU - Bhatia, Sanjiv
AU - Eastwood, Daniel
AU - Tarima, Sergey
AU - Graber, Sarah
AU - Huckins, Sean
AU - Hafez, Daniel
AU - Rumalla, Kavelin
AU - Bailey, Laurie
AU - Shandley, Sabrina
AU - Roach, Ashton
AU - Alexander, Erin
AU - Jenkins, Wendy
AU - Tsering, Deki
AU - Price, George
AU - Meola, Antonio
AU - Evanoff, Wendi
AU - Thompson, Eric M.
AU - Brandmeir, Nicholas
N1 - Publisher Copyright:
© AANS 2023.
PY - 2023/6
Y1 - 2023/6
N2 - OBJECTIVE The authors of this study evaluated the safety and efficacy of stereotactic laser ablation (SLA) for the treatment of drug-resistant epilepsy (DRE) in children. METHODS Seventeen North American centers were enrolled in the study. Data for pediatric patients with DRE who had been treated with SLA between 2008 and 2018 were retrospectively reviewed. RESULTS A total of 225 patients, mean age 12.8 ± 5.8 years, were identified. Target-of-interest (TOI) locations included extratemporal (44.4%), temporal neocortical (8.4%), mesiotemporal (23.1%), hypothalamic (14.2%), and callosal (9.8%). Visualase and NeuroBlate SLA systems were used in 199 and 26 cases, respectively. Procedure goals included ablation (149 cases), disconnection (63), or both (13). The mean follow-up was 27 ± 20.4 months. Improvement in targeted seizure type (TST) was seen in 179 (84.0%) patients. Engel classification was reported for 167 (74.2%) patients; excluding the palliative cases, 74 (49.7%), 35 (23.5%), 10 (6.7%), and 30 (20.1%) patients had Engel class I, II, III, and IV outcomes, respectively. For patients with a follow-up ≥ 12 months, 25 (51.0%), 18 (36.7%), 3 (6.1%), and 3 (6.1%) had Engel class I, II, III, and IV outcomes, respectively. Patients with a history of pre-SLA surgery related to the TOI, a pathology of malformation of cortical development, and 2+ trajectories per TOI were more likely to experience no improvement in seizure frequency and/or to have an unfavorable outcome. A greater number of smaller thermal lesions was associated with greater improvement in TST. Thirty (13.3%) patients experienced 51 short-term complications including malpositioned catheter (3 cases), intracranial hemorrhage (2), transient neurological deficit (19), permanent neurological deficit (3), symptomatic perilesional edema (6), hydrocephalus (1), CSF leakage (1), wound infection (2), unplanned ICU stay (5), and unplanned 30-day readmission (9). The relative incidence of complications was higher in the hypothalamic target location. Target volume, number of laser trajectories, number or size of thermal lesions, or use of perioperative steroids did not have a significant effect on short-term complications. CONCLUSIONS SLA appears to be an effective and well-tolerated treatment option for children with DRE. Large-volume prospective studies are needed to better understand the indications for treatment and demonstrate the long-term efficacy of SLA in this population.
AB - OBJECTIVE The authors of this study evaluated the safety and efficacy of stereotactic laser ablation (SLA) for the treatment of drug-resistant epilepsy (DRE) in children. METHODS Seventeen North American centers were enrolled in the study. Data for pediatric patients with DRE who had been treated with SLA between 2008 and 2018 were retrospectively reviewed. RESULTS A total of 225 patients, mean age 12.8 ± 5.8 years, were identified. Target-of-interest (TOI) locations included extratemporal (44.4%), temporal neocortical (8.4%), mesiotemporal (23.1%), hypothalamic (14.2%), and callosal (9.8%). Visualase and NeuroBlate SLA systems were used in 199 and 26 cases, respectively. Procedure goals included ablation (149 cases), disconnection (63), or both (13). The mean follow-up was 27 ± 20.4 months. Improvement in targeted seizure type (TST) was seen in 179 (84.0%) patients. Engel classification was reported for 167 (74.2%) patients; excluding the palliative cases, 74 (49.7%), 35 (23.5%), 10 (6.7%), and 30 (20.1%) patients had Engel class I, II, III, and IV outcomes, respectively. For patients with a follow-up ≥ 12 months, 25 (51.0%), 18 (36.7%), 3 (6.1%), and 3 (6.1%) had Engel class I, II, III, and IV outcomes, respectively. Patients with a history of pre-SLA surgery related to the TOI, a pathology of malformation of cortical development, and 2+ trajectories per TOI were more likely to experience no improvement in seizure frequency and/or to have an unfavorable outcome. A greater number of smaller thermal lesions was associated with greater improvement in TST. Thirty (13.3%) patients experienced 51 short-term complications including malpositioned catheter (3 cases), intracranial hemorrhage (2), transient neurological deficit (19), permanent neurological deficit (3), symptomatic perilesional edema (6), hydrocephalus (1), CSF leakage (1), wound infection (2), unplanned ICU stay (5), and unplanned 30-day readmission (9). The relative incidence of complications was higher in the hypothalamic target location. Target volume, number of laser trajectories, number or size of thermal lesions, or use of perioperative steroids did not have a significant effect on short-term complications. CONCLUSIONS SLA appears to be an effective and well-tolerated treatment option for children with DRE. Large-volume prospective studies are needed to better understand the indications for treatment and demonstrate the long-term efficacy of SLA in this population.
UR - http://www.scopus.com/inward/record.url?scp=85164495860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164495860&partnerID=8YFLogxK
U2 - 10.3171/2022.12.PEDS22282
DO - 10.3171/2022.12.PEDS22282
M3 - Article
C2 - 36883640
AN - SCOPUS:85164495860
SN - 1933-0707
VL - 31
SP - 551
EP - 564
JO - Journal of Neurosurgery: Pediatrics
JF - Journal of Neurosurgery: Pediatrics
IS - 6
ER -